Investors can expect that in the coming weeks Todos Medical may release its phase 2 results for Tollovir, and based on the massive moves from big pharmas, Gilead and Merck, the positive results should have a huge effect on TOMDF shares. If Todos shares jump to a valuation as much as $10 billion dollars, the share price would sit at over $10. But to be much more realistic, if TOMDF shares jumped just 1/20th as much as Gilead or Merck’s shares did, TOMDF would rise to over $0.50, or about 15x the current trading price. And a big move like this could happen in just a few weeks. Todos could then enter a phase 3 trial with Tollovir in COVID-19 hospitalized patients and quickly meet its endpoints to get the drug on the market sooner than anyone might have guessed. The company is currently very overlooked by the market and this is providing investors with a golden opportunity. It could be one of the top performing stocks in the last stretch of 2021.

https://emerginggrowth.com/mercks-molnupiravi...velopment/